MedTrace Logo

Carfilzomib in Combination for the Treatment of RR MM

NCT04004338 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-07-02

No results posted yet for this study

Summary

Carfilzomib is approved in Turkey for the treatment of adult relapsed multiple myeloma patients who have received at least one prior treatment. It is approved for use in combination with lenalidomide and dexamethasone (KRd) in and with dexamethasone alone (Kd). The purpose of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, prior therapeutic regimen chosen, and clinical outcomes in participants with relapsed/refractory (R/R) multiple myeloma (MM) who receive Carfilzomib combination treatment. Real-world evidence is crucial to understand how carfilzomib-based regimens are used in practice and in relation to local prescribing information.

This is a prospective, non-interventional, observational study.

The study population will include patients with relapsed/refractory MM who have received 1 to 3 prior lines of therapy with documented data in the medical record regarding diagnosis (month and year), the regimens used in 1st, 2nd, and 3rd line as applicable, whether stem cell transplant was part of 1st, 2nd, and 3rd line of therapy at participating clinical sites in Turkey.

Conditions

Interventions

DRUG

Kyprolis

Patients receiving kyprolis (carfilzomib)

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Black Sea Hematology Association

    lead OTHER

Principal Investigators

  • Mehmet Turgut, Prof · 19 Mayıs University Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-14
Primary Completion
2021-04-14
Completion
2021-04-14

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004338 on ClinicalTrials.gov